A report by experts released by the Food and Drug Administration (FDA) on Monday raised doubts as to whether the vaccine developed by United Biomedical Inc (UBI) Asia offers sufficient protection against COVID-19 variants.
According to the report, a panel of 22 experts at a review meeting on Aug. 15, which denied a request from UBI for emergency use authorization (EUA) for its vaccine candidate UB-612, suggested that the company should conduct a third phase of clinical trials to determine the jab’s efficacy.
At the meeting, 17 of the experts, not counting the chairman, voted against UBI’s request for an EUA, as the vaccine candidate failed to meet approval standards, while the remaining four asked the company to submit more documents for another review.
For a vaccine to be granted an EUA by the FDA, it has to have a seroconversion rate of more than 50 percent and virus neutralizing antibodies — expressed as geometric mean titers (GMTs) — at least equal to two-thirds the level found in recipients of the AstraZeneca vaccine.
UBI has said that its vaccine candidate is expected to protect those inoculated against the Delta variant of SARS-CoV-2, which is now the most transmittable and contagious variant worldwide.
However, the report said that the GMT of UBI’s vaccine candidate declined at a moderate pace when faced with virus variants and based on the limited information available it is hard to say whether people who receive the vaccine would be protected against the Delta and Alpha variants.
The report also cited some experts on the panel as saying that UBI’s vaccine did not even appear to be effective against the original SARS-CoV-2 virus.
However, some other experts on the panel said that peptides inside the vaccine still have the potential to create protection against variants of SARS-CoV-2, suggesting that UBI should conduct a third phase 3 clinical trial.
They added that it remains to be seen how the vaccine creates a response to T-cells.
On Aug. 22, UBI founder Wang Chang-yi (王長怡) said that the FDA’s standards for granting EUAs were hastily designed and outdated.
She said that it would be deeply regrettable to deny people access to such a good vaccine because of hastily devised EUA standards.
Despite its application being rejected in Taiwan, UBI remains committed to seeking international approval for its COVID-19 vaccine candidate, Wang said.
The company plans to conduct phase 3 clinical trials in India for its “next generation” COVID-19 vaccine, named “UB-613,” she said.
The FDA decided to test antibody concentrations against people who have been immunized with the AstraZeneca vaccine because there is no uniform, globally accepted method of measuring GMTs or how high the GMT level should be to indicate protection.
The manufacture of the remaining 28 M1A2T Abrams tanks Taiwan purchased from the US has recently been completed, and they are expected to be delivered within the next one to two months, a source said yesterday. The Ministry of National Defense is arranging cargo ships to transport the tanks to Taiwan as soon as possible, said the source, who is familiar with the matter. The estimated arrival time ranges from late this month to early next month, the source said. The 28 Abrams tanks make up the third and final batch of a total of 108 tanks, valued at about NT$40.5 billion
Two Taiwanese prosecutors were questioned by Chinese security personnel at their hotel during a trip to China’s Henan Province this month, the Mainland Affairs Council (MAC) said yesterday. The officers had personal information on the prosecutors, including “when they were assigned to their posts, their work locations and job titles,” MAC Deputy Minister and spokesman Liang Wen-chieh (梁文傑) said. On top of asking about their agencies and positions, the officers also questioned the prosecutors about the Cross-Strait Joint Crime-Fighting and Judicial Mutual Assistance Agreement, a pact that serves as the framework for Taiwan-China cooperation on combating crime and providing judicial assistance, Liang
A group from the Taiwanese Designers in Australia association yesterday represented Taiwan at the Midsumma Pride March in Melbourne. The march, held in the St. Kilda suburb, is the city’s largest LGBTQIA+ parade and the flagship event of the annual Midsumma Festival. It attracted more than 45,000 spectators who supported the 400 groups and 10,000 marchers that participated this year, the association said. Taiwanese Designers said they organized a team to march for Taiwan this year, joining politicians, government agencies, professionals and community organizations in showing support for LGBTQIA+ people and diverse communities. As the first country in Asia to legalize same-sex
MOTIVES QUESTIONED The PLA considers Xi’s policies toward Taiwan to be driven by personal considerations rather than military assessment, the Epoch Times reports Chinese President Xi Jinping’s (習近平) latest purge of the Chinese People’s Liberation Army (PLA) leadership might have been prompted by the military’s opposition to plans of invading Taiwan, the Epoch Times said. The Chinese military opposes waging war against Taiwan by a large consensus, putting it at odds with Xi’s vision, the Falun Gong-affiliated daily said in a report on Thursday, citing anonymous sources with insight into the PLA’s inner workings. The opposition is not the opinion of a few generals, but a widely shared view among the PLA cadre, the Epoch Times cited them as saying. “Chinese forces know full well that
RSS